Hilary Calvert
- Oncology top 1%
- Cancer Treatment and Pharmacology 17
- Colorectal Cancer Treatments and Studies 14
- PARP inhibition in cancer therapy 10
- HER2/EGFR in Cancer Research 9
- Cancer-related Molecular Pathways 8
- Genetics top 1%
-
- Lung Cancer Treatments and Mutations 19
- Cancer Research top 5%
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 12
- DNA Repair Mechanisms 7
- Co-authors
- Henry S. FriedmanTracy KerbyRuth PlummerAdrian L. HarrisStan B. KayeAlan V. BoddyRichard H. WilsonMalcolm Ranson
- Journals
- Journal of Clinical Oncology (14 papers)The Lancet Oncology (1 paper)Clinical Cancer Research (7 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Hilary Calvert
79 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Oncology 2.6k
- Genetics 765
- Pulmonary and Respiratory Medicine 1.5k
- Cancer Research 610
- Molecular Biology 2.2k
Countries citing papers authored by Hilary Calvert
This map shows the geographic impact of Hilary Calvert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilary Calvert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilary Calvert more than expected).
Fields of papers citing papers by Hilary Calvert
This network shows the impact of papers produced by Hilary Calvert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilary Calvert. The network helps show where Hilary Calvert may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hilary Calvert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 23 | |
| 2 | 2012 | 13 | |
| 3 | 2011 | 52 | |
| 4 | 2011 | 39 | |
| 5 | 2011 | 23 | |
| 6 | 2011 | 24 | |
| 7 | 2010 | 295 | |
| 8 | 2009 | 1 | |
| 9 | 2009 | 40 | |
| 10 | 2008 | 291 | |
| 11 | 2008 | 42 | |
| 12 | 2007 | 198 | |
| 13 | 2007 | 6 | |
| 14 | 2003 | 11 | |
| 15 | 2003 | 3 | |
| 16 | Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. | 2003 | 40 |
| 17 | 2002 | 16 | |
| 18 | 2002 | 42 | |
| 19 | 2002 | 82 | |
| 20 | 2001 | 26 |
About Hilary Calvert
Hilary Calvert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine, having authored 79 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (19 papers), Cancer Treatment and Pharmacology (17 papers), Colorectal Cancer Treatments and Studies (14 papers), Cancer therapeutics and mechanisms (12 papers), PARP inhibition in cancer therapy (10 papers), HER2/EGFR in Cancer Research (9 papers), Cancer-related Molecular Pathways (8 papers) and DNA Repair Mechanisms (7 papers). The work is most often cited by research in Oncology (2.6k citations), Genetics (765 citations) and Pulmonary and Respiratory Medicine (1.5k citations). Hilary Calvert has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Henry S. Friedman, Tracy Kerby, Ruth Plummer, Adrian L. Harris, Stan B. Kaye, Alan V. Boddy, Richard H. Wilson, Malcolm Ranson, Helen Swaisland and Éric Raymond. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.